M Toulmonde1, A Le Cesne2, S Piperno-Neumann3, N Penel4, C Chevreau5, F Duffaud6, C Bellera7, A Italiano8. 1. Department of Medical Oncology, Institut Bergonié, Bordeaux. 2. Department of Medicine, Institut Gustave Roussy, Villejuif. 3. Department of Medicine, Institut Curie, Paris. 4. Department of Medicine, Centre Oscar Lambret, Lille. 5. Department of Medicine, Institut Claudius Regaud, Toulouse. 6. Department of Medical Oncology, Hôpital La Timone, Marseille. 7. Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux Data Center for Cancer Clinical Trials, CTD-INCa, Bordeaux, France. 8. Department of Medical Oncology, Institut Bergonié, Bordeaux a.italiano@bordeaux.unicancer.fr.
Abstract
BACKGROUND: Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase. METHODS: This phase II trial included patients with progressive advanced DDLPS. They received Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity. The primary end point was the 3-month nonprogression rate (PFS3) defined as the proportion of patients with nonprogressive disease at 3 months. A PFS3 of 40% considered as a reasonable objective to claim drug efficacy. RESULTS: Between August 2012 and May 2013, 24 patients were included. Sixteen had received prior chemotherapy. Twenty-two were assessable for efficacy. The PFS3 was 9.1% [95% confidence interval (CI) 1.1-29.2]. Median progression-free and overall survivals were 1.6 months (95% CI 1.4-2.6) and 9.2 months (95% CI 6.6-). The most frequent adverse events of any grade were nausea, fatigue, anorexia, vomiting and diarrhea. CONCLUSION: Aplidin did not meet the primary end point of this trial and do not deserve further investigation in DDLPS. CLINICALTRIALSGOV IDENTIFIER: NCT01876043.
BACKGROUND: Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase. METHODS: This phase II trial included patients with progressive advanced DDLPS. They received Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity. The primary end point was the 3-month nonprogression rate (PFS3) defined as the proportion of patients with nonprogressive disease at 3 months. A PFS3 of 40% considered as a reasonable objective to claim drug efficacy. RESULTS: Between August 2012 and May 2013, 24 patients were included. Sixteen had received prior chemotherapy. Twenty-two were assessable for efficacy. The PFS3 was 9.1% [95% confidence interval (CI) 1.1-29.2]. Median progression-free and overall survivals were 1.6 months (95% CI 1.4-2.6) and 9.2 months (95% CI 6.6-). The most frequent adverse events of any grade were nausea, fatigue, anorexia, vomiting and diarrhea. CONCLUSION: Aplidin did not meet the primary end point of this trial and do not deserve further investigation in DDLPS. CLINICALTRIALSGOV IDENTIFIER: NCT01876043.
Authors: A Italiano; M Toulmonde; A Cioffi; N Penel; N Isambert; E Bompas; F Duffaud; A Patrikidou; B Lortal; A Le Cesne; J-Y Blay; R G Maki; G K Schwartz; C R Antonescu; S Singer; J-M Coindre; B Bui Journal: Ann Oncol Date: 2011-10-29 Impact factor: 32.976
Authors: Susana B Bravo; María E R García-Rendueles; Rafael Seoane; Vanesa Dosil; José Cameselle-Teijeiro; Luis López-Lázaro; Juan Zalvide; Francisco Barreiro; Celia M Pombo; Clara V Alvarez Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Chiara Mussi; Paola Collini; Rosalba Miceli; Marta Barisella; Luigi Mariani; Marco Fiore; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Roberta Sanfilippo; Rossella Bertulli; Andrea Marrari; Elena Fumagalli; Silvana Pilotti; Carlo Morosi; Antonella Messina; Angelo Paolo Dei Tos; Alessandro Gronchi; Paolo Giovanni Casali Journal: Clin Sarcoma Res Date: 2014-11-22
Authors: Sara Alonso-Álvarez; Emilia Pardal; Diego Sánchez-Nieto; Miguel Navarro; Maria Dolores Caballero; Maria Victoria Mateos; Alejandro Martín Journal: Drug Des Devel Ther Date: 2017-01-19 Impact factor: 4.162
Authors: Qi-Ting Zhang; Ze-Dong Liu; Ze Wang; Tao Wang; Nan Wang; Ning Wang; Bin Zhang; Yu-Fen Zhao Journal: Mar Drugs Date: 2021-02-19 Impact factor: 5.118